Vertex Revises CF Combo Data Showing Less Benefit

Vertex Pharmaceuticals Inc. sank the most in three years after the company revised results reported three weeks ago from a study of two cystic fibrosis drugs, saying the combination showed less of a benefit.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.